How do I safely discontinue Xanax (alprazolam) XL?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Safely Discontinuing Xanax (Alprazolam) XL

Alprazolam should be discontinued gradually by reducing the dose by no more than 0.5 mg every 3 days to prevent withdrawal symptoms, with some patients requiring an even slower tapering schedule. 1

Assessment Before Tapering

  • Document baseline symptoms, medication history including duration of use and daily dose before initiating withdrawal 2
  • Patients at high risk for severe withdrawal (history of seizures, medical comorbidities) may require inpatient management 2
  • Educate patients about potential withdrawal symptoms and benefits of tapering, as this approach has shown success in facilitating withdrawal 2

Tapering Protocol for Alprazolam

  • Reduce the daily dose by no more than 0.5 mg every 3 days as recommended in the FDA label 1
  • For long-term users, consider an even slower tapering schedule extending over several weeks to months 1, 2
  • Some patients may require an extremely gradual taper, especially those on high doses or with prolonged use 1, 3
  • If withdrawal symptoms become severe, temporarily return to the previous dose before continuing with a more gradual taper 2

Managing Withdrawal Symptoms

  • Common withdrawal symptoms include insomnia (29.5%), anxiety (19.2%), light-headedness (19.3%), fatigue (18.4%), headache (17%), abnormal involuntary movements (17.3%), nausea/vomiting (16.5%), and sweating (14.4%) 1
  • More serious withdrawal symptoms can include seizures, which have been reported with abrupt discontinuation 1, 4
  • Use a standardized scoring system to assess withdrawal symptoms during the tapering process 2
  • For breakthrough anxiety or agitation, consider using the lowest effective dose of alprazolam rather than adding different medications 2

Adjunctive Treatments

  • Consider non-pharmacological interventions including cognitive-behavioral therapy, supportive psychotherapy, relaxation techniques, and patient education 2, 5
  • Psychological support should be available both during dosage reduction and for some months after cessation 3
  • Adjunctive medications may occasionally be required (antidepressants, propranolol) but no drugs have been proven to be of general utility in alleviating withdrawal symptoms 3

Special Considerations

  • Elderly patients, those with advanced liver disease, or debilitating conditions may require starting at lower doses (0.25 mg) and more gradual tapering 1
  • Success rates of withdrawal are high and are unaffected by duration of usage, dosage or type of benzodiazepine, rate of withdrawal, symptom severity, psychiatric history or personality disorder 3
  • Unwilling patients should not be forced to withdraw 3

Follow-up and Monitoring

  • Regular follow-up appointments to assess withdrawal symptoms and adjust the tapering schedule as needed 2
  • Monitor for at least 2 months after discontinuation to distinguish between withdrawal symptoms and relapse 6
  • Consider referral to addiction specialists for patients with severe dependence or complicated withdrawal 2

Common Pitfalls to Avoid

  • Tapering too quickly, which can precipitate severe withdrawal symptoms including seizures 4, 7
  • Abrupt discontinuation, which significantly increases risk of withdrawal syndrome and rebound symptoms 1, 8
  • Failing to address underlying reasons for alprazolam use 2
  • Underestimating the potential for withdrawal symptoms even in patients taking therapeutic doses for short periods 7

References

Guideline

Managing Benzodiazepine Withdrawal

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The treatment of benzodiazepine dependence.

Addiction (Abingdon, England), 1994

Research

Benzodiazepine withdrawal seizures and management.

The Journal of the Oklahoma State Medical Association, 2011

Guideline

Risks of Abrupt Discontinuation of SSRIs and Tapering Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Benzodiazepine withdrawal syndrome: a literature review and evaluation.

The American journal of drug and alcohol abuse, 1982

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.